Currently, imaging agent pH001, as a novel nuclear imaging marker of diseased tissue acidity is in Phase I clinical trials at the Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier: NCT04054986
Study Title: Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
Imaging agent pH002, is in the process of clinical translation as a novel marker of blood flow and as an imaging agent for visualization of cancerous lesions in primary tumors and lymph nodes.
Clinical trials will be initiated at the Memorial Sloan Kettering Cancer Center in 2020.